Florence Abravanel

List of Publications by Year
in descending order

167 papers	12,562 citations	29994 54 h-index	27345 106 g-index
176 all docs	176 docs citations	176 times ranked	8594 citing authors

#	Article	IF	Citations
1	Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients. New England Journal of Medicine, 2008, 358, 811-817.	13.9	1,197
2	Hepatitis E. Lancet, The, 2012, 379, 2477-2488.	6.3	805
3	Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. New England Journal of Medicine, 2021, 385, 661-662.	13.9	728
4	Insertions and Duplications in the Polyproline Region of the Hepatitis E Virus. Frontiers in Microbiology, 2020, 11, 1.	1.5	599
5	Hepatitis E Virus Infection. Clinical Microbiology Reviews, 2014, 27, 116-138.	5.7	512
6	Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. New England Journal of Medicine, 2014, 370, 1111-1120.	13.9	436
7	Hepatitis E Virus Antibodies in Blood Donors, France. Emerging Infectious Diseases, 2011, 17, 2309-2312.	2.0	314
8	Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection. Gastroenterology, 2010, 139, 1612-1618.	0.6	265
9	Hepatitis E in the south west of France in individuals who have never visited an endemic area. Journal of Medical Virology, 2004, 74, 419-424.	2.5	232
10	Hepatitis E Virus Strains in Rabbits and Evidence of a Closely Related Strain in Humans, France. Emerging Infectious Diseases, 2012, 18, 1274-81.	2.0	221
11	Hepatitis E Virus-Related Cirrhosis in Kidneyand Kidney-Pancreas-Transplant Recipients. American Journal of Transplantation, 2008, 8, 1744-1748.	2.6	209
12	Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation. Transplantation, 2010, 89, 353-360.	0.5	201
13	Pegylated Interferonâ€Î± for Treating Chronic Hepatitis E Virus Infection after Liver Transplantation. Clinical Infectious Diseases, 2010, 50, e30-e33.	2.9	180
14	Characteristics of Autochthonous Hepatitis E Virus Infection in Solidâ€Organ Transplant Recipients in France. Journal of Infectious Diseases, 2010, 202, 835-844.	1.9	174
15	Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients. Transplantation, 2012, 93, 617-623.	0.5	170
16	High prevalence of antiâ€hepatitis E virus antibodies in blood donors from South West France. Journal of Medical Virology, 2008, 80, 289-293.	2.5	162
17	Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. Gastroenterology, 2018, 154, 211-223.e8.	0.6	145
18	Hepatitis E Virus Genotype 3 Diversity, France. Emerging Infectious Diseases, 2009, 15, 110-114.	2.0	141

#	Article	IF	Citations
19	Rabbit Hepatitis E Virus Infections in Humans, France. Emerging Infectious Diseases, 2017, 23, 1191-1193.	2.0	139
20	Hepatitis E Virus Reinfections in Solid-Organ-Transplant Recipients Can Evolve Into Chronic Infections. Journal of Infectious Diseases, 2014, 209, 1900-1906.	1.9	136
21	Hepatitis E Virus Infection without Reactivation in Solid-Organ Transplant Recipients, France. Emerging Infectious Diseases, 2011, 17, 30-37.	2.0	134
22	Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland. Emerging Infectious Diseases, 2011, 17, 1074-1078.	2.0	123
23	Safety and Immunogenicity of Antiâ€"SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants. Annals of Internal Medicine, 2021, 174, 1336-1338.	2.0	122
24	Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 322-323.	2.6	120
25	Hepatitis E Virus Infections in Blood Donors, France. Emerging Infectious Diseases, 2014, 20, 1914-1917.	2.0	118
26	Monitoring human enteric viruses in wastewater and relevance to infections encountered in the clinical setting: a one-year experiment in central France, 2014 to 2015. Eurosurveillance, 2018, 23, .	3.9	116
27	Acute hepatitis E in south-west France over a 5-year period. Journal of Clinical Virology, 2009, 44, 74-77.	1.6	114
28	Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. Gut, 2017, 66, 920-929.	6.1	113
29	How Should Hepatitis E Virus Infection Be Defined in Organ-Transplant Recipients?. American Journal of Transplantation, 2013, 13, 1935-1936.	2.6	112
30	Genotype 3 Diversity and Quantification of Hepatitis E Virus RNA. Journal of Clinical Microbiology, 2012, 50, 897-902.	1.8	110
31	New Natural Intergenotypic (2/5) Recombinant of Hepatitis C Virus. Journal of Virology, 2007, 81, 4357-4362.	1.5	103
32	Assessment of 4 Doses of SARS-CoV-2 Messenger RNAâ€"Based Vaccine in Recipients of a Solid Organ Transplant. JAMA Network Open, 2021, 4, e2136030.	2.8	103
33	Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. Journal of Clinical Virology, 2013, 58, 624-628.	1.6	98
34	Extrahepatic manifestations of hepatitis E virus. Liver International, 2016, 36, 467-472.	1.9	98
35	Characterization of the lipid envelope of exosome encapsulated HEV particles protected from the immune response. Biochimie, 2017, 141, 70-79.	1.3	98
36	Hepatitis E Virus Quasispecies and the Outcome of Acute Hepatitis E in Solid-Organ Transplant Patients. Journal of Virology, 2012, 86, 10006-10014.	1.5	97

#	Article	IF	Citations
37	Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrology Dialysis Transplantation, 2010, 25, 2792-2795.	0.4	92
38	High Proportion of Asymptomatic Infections in an Outbreak of Hepatitis E Associated With a Spit-Roasted Piglet, France, 2013. Clinical Infectious Diseases, 2016, 62, 351-357.	2.9	92
39	Good Performance of Immunoglobulin M Assays in Diagnosing Genotype 3 Hepatitis E Virus Infections. Vaccine Journal, 2009, 16, 772-774.	3.2	80
40	Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. Journal of Hepatology, 2017, 67, 925-932.	1.8	80
41	Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 20-27.	0.7	78
42	New NS5B polymerase inhibitors for hepatitis C. Expert Opinion on Investigational Drugs, 2010, 19, 963-975.	1.9	77
43	Hepatitis E Pathogenesis. Viruses, 2016, 8, 212.	1.5	77
44	Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. Clinical Infectious Diseases, 2020, 71, 1204-1211.	2.9	74
45	Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. Journal of Clinical Medicine, 2020, 9, 331.	1.0	73
46	Heterogeneity of hepatitis C virus genotype 4 strains circulating in south-western France. Journal of General Virology, 2005, 86, 107-114.	1.3	71
47	Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland. Emerging Infectious Diseases, 2011, 17, 1074-1078.	2.0	64
48	Protracted Fecal Shedding of HEV During Ribavirin Therapy Predicts Treatment Relapse. Clinical Infectious Diseases, 2015, 60, 96-99.	2.9	62
49	Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy. Antimicrobial Agents and Chemotherapy, 2016, 60, 1608-1614.	1.4	62
50	Treatment of autochthonous acute hepatitis E with shortâ€term ribavirin: a multicenter retrospective study. Liver International, 2016, 36, 328-333.	1.9	61
51	An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation, 2015, 99, 2124-2131.	0.5	60
52	Characterization of the Polyproline Region of the Hepatitis E Virus in Immunocompromised Patients. Journal of Virology, 2014, 88, 12017-12025.	1.5	58
53	Hepatitis E Virusâ€“Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person. American Journal of Kidney Diseases, 2016, 67, 660-663.	2.1	58
54	Hepatitis E virus replication in human intestinal cells. Gut, 2020, 69, 901-910.	6.1	58

#	Article	IF	Citations
55	Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E. Emerging Infectious Diseases, 2015, 21, 1928-34.	2.0	57
56	Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. Journal of Medical Virology, 2009, 81, 2029-2035.	2.5	56
57	Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. Journal of Clinical Virology, 2012, 54, 152-155.	1.6	56
58	Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. American Journal of Kidney Diseases, 2005, 45, 193-196.	2.1	55
59	Hepatitis C Virus Genotype 5: Epidemiological Characteristics and Sensitivity to Combination Therapy with Interferonâ€Î± plus Ribavirin. Journal of Infectious Diseases, 2004, 189, 1397-1400.	1.9	53
60	Hepatitis E Virus: What Transplant Physicians Should Know. American Journal of Transplantation, 2012, 12, 2281-2287.	2.6	53
61	Influence of Polyproline Region and Macro Domain Genetic Heterogeneity on HEV Persistence in Immunocompromised Patients. Journal of Infectious Diseases, 2014, 209, 300-303.	1.9	53
62	Risk of zoonotic transmission of HEV from rabbits. Journal of Clinical Virology, 2013, 58, 357-362.	1.6	52
63	Molecular Evidence of Patientâ€toâ€Patient Transmission of Hepatitis E Virus in a Hematology Ward. Clinical Infectious Diseases, 2009, 48, 373-374.	2.9	51
64	Sofosbuvir and Daclatasvir Antiâ€“Viral Therapy Fails toÂClear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient. Gastroenterology, 2017, 152, 300-301.	0.6	51
65	Acute hepatitis E in French patients and neurological manifestations. Journal of Infection, 2018, 77, 220-226.	1.7	51
66	An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population. PLoS ONE, 2013, 8, e62980.	1.1	51
67	Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. Journal of Medical Virology, 2005, 77, 66-69.	2.5	50
68	NS3 Protease Polymorphism and Natural Resistance to Protease Inhibitors in French Patients Infected with HCV Genotypes 1â€“5. Antiviral Therapy, 2011, 16, 1093-1102.	0.6	50
69	Outcome of Hepatitis E Virus Infection in Patients With Inflammatory Arthritides Treated With Immunosuppressants. Medicine (United States), 2015, 94, e675.	0.4	50
70	Performance of Two Commercial Assays for Detecting Hepatitis E Virus RNA in Acute or Chronic Infections. Journal of Clinical Microbiology, 2013, 51, 1913-1916.	1.8	48
71	Molecular Epidemiology and Interferon Susceptibility of the Natural Recombinant Hepatitis C Virus Strain RF1_2k/1b. Journal of Infectious Diseases, 2008, 198, 1448-1456.	1.9	47
72	Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma. Antiviral Research, 2017, 141, 150-154.	1.9	46

#	Article	IF	Citations
73	Hepatitis E virus infections in Europe. Journal of Clinical Virology, 2019, 120, 20-26.	1.6	46
74	Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection. Journal of Clinical Virology, 2016, 79, 1-5.	1.6	44
75	Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. Emerging Infectious Diseases, 2015, 21, 1466-1469.	2.0	41
76	Vectorial Release of Hepatitis E Virus in Polarized Human Hepatocytes. Journal of Virology, 2019, 93, .	1.5	41
77	Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients. American Journal of Transplantation, 2022, 22, 1467-1474.	2.6	37
78	Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. Journal of Medical Virology, 2008, 80, 1523-1529.	2.5	36
79	Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis. Viruses, 2016, 8, 222.	1.5	36
80	Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France. Infection, Genetics and Evolution, 2015, 35, 50-55.	1.0	33
81	Diversity of hepatitis E virus genotype 3. Reviews in Medical Virology, 2018, 28, e1987.	3.9	33
82	Hepatitis E, the neglected one. Liver International, 2016, 36, 130-134.	1.9	32
83	Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients. Journal of Infection, 2019, 78, 232-240.	1.7	31
84	Evaluation of the Aptimaâ„¢ transcription-mediated amplification assay (HologicÂ®) for detecting SARS-CoV-2 in clinical specimens. Journal of Clinical Virology, 2020, 129, 104541.	1.6	31
85	Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes. Frontiers in Microbiology, 2020, 11, 634430.	1.5	31
86	HEV and transfusion-recipient risk. Transfusion Clinique Et Biologique, 2017, 24, 176-181.	0.2	30
87	Hepatitis E virusâ€“associated cryoglobulinemia in solidâ€organâ€“transplant recipients. Liver International, 2018, 38, 2178-2189.	1.9	29
88	Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis. Transplant International, 2009, 22, 568-573.	0.8	28
89	HEV infection in French HIV-infected patients. Journal of Infection, 2017, 74, 310-313.	1.7	27
90	Chronic Hepatitis E in a Heart Transplant Patient: Sofosbuvir and Ribavirin Regimen Not Fully Effective. Antiviral Therapy, 2018, 23, 463-465.	0.6	27

#	Article	IF	Citations
91	Epidemiological and virological characteristics of symptomatic acute hepatitis E in Greater Cairo, Egypt. Clinical Microbiology and Infection, 2012, 18, 982-988.	2.8	26
92	Quantification of HEV RNA by Droplet Digital PCR. Viruses, 2016, 8, 233.	1.5	26
93	Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients. Journal of Hepatology, 2019, 70, 206-209.	1.8	26
94	Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients. Journal of Infection, 2016, 72, 723-730.	1.7	25
95	Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France. Emerging Infectious Diseases, 2017, 23, 353-356.	2.0	25
96	Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients. Transplantation Direct, 2022, 8, e1248.	0.8	25
97	Genetic diversity of HCV genotype 2 strains in South Western France. Journal of Medical Virology, 2007, 79, 26-34.	2.5	24
98	Screening, diagnosis and risks associated with Hepatitis E virus infection. Expert Review of Anti-Infective Therapy, 2019, 17, 403-418.	2.0	23
99	Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114946.	0.8	23
100	Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. Microbiology Spectrum, 2021, 9, e0137621.	1.2	22
101	Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin. Journal of Clinical Microbiology, 2015, 53, 2195-2202.	1.8	21
102	Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. Annals of Internal Medicine, 2020, 173, 501-503.	2.0	21
103	Hepatitis E virus. MÃ©decine Et Maladies Infectieuses, 2013, 43, 263-270.	5.1	20
104	Frequent Transient Hepatitis C viremia without Seroconversion among Healthcare Workers in Cairo, Egypt. PLoS ONE, 2013, 8, e57835.	1.1	20
105	New insights into the natural history of hepatitis E virus infection through a longitudinal study of multitransfused immunocompetent patients in France. Journal of Viral Hepatitis, 2016, 23, 569-575.	1.0	20
106	Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis. Journal of Infectious Diseases, 2019, 220, 811-819.	1.9	20
107	Does HEVâ€3 subtype play a role in the severity of acute hepatitis E?. Liver International, 2020, 40, 333-337.	1.9	20
108	Performance of a new rapid test for detecting anti-hepatitis E virus immunoglobulin M in immunocompetent and immunocompromised patients. Journal of Clinical Virology, 2015, 70, 101-104.	1.6	19

#	Article	IF	Citations
109	Hepatitis E, whatâ€™s the real issue?. Liver International, 2020, 40, 43-47.	1.9	19
110	Chronic Genotype 3 Hepatitis E in Pregnant Woman Receiving Infliximab and Azathioprine. Emerging Infectious Diseases, 2018, 24, 941-943.	2.0	18
111	Transmission of HCV NS5A Inhibitorâ€"Resistant Variants Among HIV-Infected Men Who Have Sex With Men. Clinical Infectious Diseases, 2016, 63, ciw554.	2.9	17
112	Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly. PLoS Pathogens, 2021, 17, e1009367.	2.1	16
113	Full-length genome sequences of hepatitis C virus subtype 4f. Journal of General Virology, 2007, 88, 2985-2990.	1.3	15
114	Detection and quantitation of HCV RNA using realâ€time PCR after automated sample processing. Journal of Medical Virology, 2007, 79, 1821-1826.	2.5	15
115	Optimized Hepatitis E Virus (HEV) Culture and Its Application to Measurements of HEV Infectivity. Viruses, 2020, 12, 139.	1.5	15
116	Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. Journal of Medical Virology, 2006, 78, 365-371.	2.5	14
117	Evolutionary history of hepatitis C virus genotype 5a in France, a multicenter ANRS study. Infection, Genetics and Evolution, 2011, 11, 496-503.	1.0	14
118	Hepatitis E in Transplantation. Current Infectious Disease Reports, 2016, 18, 8.	1.3	14
119	Chronic hepatitis E virus infection in a cirrhotic patient. Medicine (United States), 2017, 96, e7915.	0.4	14
120	Transfusionâ€acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient. Transplant Infectious Disease, 2017, 19, e12784.	0.7	14
121	Performance evaluation of the Vela Dx Sentosa next-generation sequencing system for HIV-1 DNA genotypic resistance. Journal of Clinical Virology, 2020, 122, 104229.	1.6	14
122	Clinical performance of a rapid test compared to a microplate test to detect total anti SARS-CoV-2 antibodies directed to the spike protein. Journal of Clinical Virology, 2020, 130, 104528.	1.6	14
123	Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. Journal of Infection, 2021, 82, e29-e32.	1.7	14
124	Hepatitis E Virus: How It Escapes Host Innate Immunity. Vaccines, 2020, 8, 422.	2.1	13
125	Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World Journal of Hepatology, 2014, 6, 660.	0.8	13
126	Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load. Viruses, 2022, 14, 323.	1.5	13

#	Article	IF	Citations
127	Hepatitis E Virus Infection: Neurological Manifestations and Pathophysiology. Pathogens, 2021, 10, 1582.	1.2	13
128	Performance characteristics of the VIDASÂ® ANTI-HEV IgM and IgG assays. Journal of Clinical Virology, 2019, 112, 10-14.	1.6	12
129	Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. Journal of Viral Hepatitis, 2019, 26, 1139-1142.	1.0	12
130	Seroprevalence of hepatitis E virus (HEV) in a general adult population in Northern Norway: the TromsÃ¸ study. Medical Microbiology and Immunology, 2019, 208, 715-725.	2.6	12
131	Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response. Clinical Immunology, 2022, 237, 108979.	1.4	12
132	Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers. Journal of Clinical Virology, 2009, 44, 134-137.	1.6	9
133	Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world. Journal of Hepatology, 2018, 68, 595-597.	1.8	9
134	Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. Viruses, 2019, 11, 630.	1.5	9
135	Hepatitis E and Allogeneic Hematopoietic Stem Cell Transplantation: A French Nationwide SFGM-TC Retrospective Study. Viruses, 2019, 11, 622.	1.5	9
136	Failure to respond to ribavirin despite elevated intraâ€erythrocyte zinc level in transplantâ€patients with chronic hepatitis E virus infection. Transplant Infectious Disease, 2019, 21, e13050.	0.7	9
137	Hepatitis E virus-specific T-cell response after transplantation. Hepatology, 2012, 55, 1643-1643.	3.6	8
138	Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA. Journal of Clinical Virology, 2016, 84, 7-11.	1.6	8
139	Hepatitis E prevalence in French Polynesian blood donors. PLoS ONE, 2018, 13, e0208934.	1.1	8
140	Risk for Hepatitis E Virus Transmission by Solvent/Detergentâ€"Treated Plasma. Emerging Infectious Diseases, 2020, 26, 2881-2886.	2.0	8
141	Rat Hepatitis E Virus: Presence in Humans in South-Western France?. Frontiers in Medicine, 2021, 8, 726363.	1.2	8
142	Testing individual and pooled saliva samples for sars-cov-2 nucleic acid: a prospective study. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115478.	0.8	8
143	Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations. Vaccines, 2021, 9, 1205.	2.1	8
144	Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine. Vaccines, 2022, 10, 354.	2.1	8

#	Article	IF	Citations
145	Evaluation of two VIDAS Â® prototypes for detecting anti-HEV IgG. Journal of Clinical Virology, 2017, 89, 46-50.	1.6	7
146	Parsonage-Turner syndrome due to autochthonous acute genotype 3f hepatitis E virus infection in a nonimmunocompromised 55-year-old patient. Journal of NeuroVirology, 2017, 23, 615-620.	1.0	7
147	A fully automated system using transcription-mediated amplification for the molecular diagnosis of hepatitis E virus in human blood and faeces. Journal of Clinical Virology, 2018, 105, 109-111.	1.6	7
148	Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso. Viruses, 2019, 11, 554.	1.5	7
149	No evidence of sexual transmission of HEV among individuals using HIV preâ€exposure prophylaxis. Journal of Viral Hepatitis, 2020, 27, 1495-1501.	1.0	7
150	Convenient Biological Assay for Polyethylene Glycol-Interferons in Patients with Hepatitis C. Antimicrobial Agents and Chemotherapy, 2004, 48, 3610-3612.	1.4	6
151	Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients. Journal of Clinical Virology, 2015, 69, 203-209.	1.6	6
152	Performance of a commercial assay for detecting and quantifying HEV RNA in faeces. Journal of Clinical Virology, 2018, 109, 1-5.	1.6	6
153	Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients. Open Forum Infectious Diseases, 2019, 6, ofz345.	0.4	6
154	Analyses of Clinical and Biological Data for French and Belgian Immunocompetent Patients Infected With Hepatitis E Virus Genotypes 4 and 3. Frontiers in Microbiology, 2021, 12, 645020.	1.5	6
155	Hepatitis E, what is the real issue?. Liver International, 2021, 41, 68-72.	1.9	6
156	An Evaluation of Hepatitis E Virus Molecular Typing Methods. Clinical Chemistry, 2021, 68, 181-191.	1.5	5
157	Fatal encephalitis and Borna Disease Virusâ€1 seropositivity in two kidneyâ€transplant patients living in the same nonendemic area. Transplant Infectious Disease, 2021, 23, .	0.7	5
158	Mobilization of Î³Î´ T Cells and IL-10 Production at the Acute Phase of Hepatitis E Virus Infection in Cytomegalovirus Carriers. Journal of Immunology, 2021, 206, 1027-1038.	0.4	5
159	Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay. Viruses, 2022, 14, 1065.	1.5	5
160	HIV-1 Tropism and Liver Fibrosis in HIVâ€“HCV Co-Infected Patients. PLoS ONE, 2012, 7, e50289.	1.1	4
161	Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort. Antiviral Therapy, 2018, 23, 307-314.	0.6	4
162	Should 12â€•or 24â€week postâ€ribavirin followâ€up be considered to define sustained virological response in transplant patients treated for chronic hepatitis E virus infection?. Transplant Infectious Disease, 2019, 21, e13065.	0.7	4

#	Article	IF	Citations
163	No evidence of occult hepatitis C or E virus infections in liverâ€transplant patients with sustained virological response after therapy with direct acting agents. Transplant Infectious Disease, 2019, 21, e13093.	0.7	4
164	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. Kidney International, 2021, 100, 915-927.	2.6	4
165	Multicenter Quality Control of Hepatitis C Virus Protease Inhibitor Resistance Genotyping. Journal of Clinical Microbiology, 2013, 51, 1428-1433.	1.8	3
166	Malignancies in hepatitis C virusâ€positive and â€negative kidney transplant recipients: A caseâ€controlled study. Transplant Infectious Disease, 2017, 19, e12725.	0.7	3
167	Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma. PLoS ONE, 2017, 12, e0174651.	1.1	1